Skip to main content
NASDAQ:ENVB

Enveric Biosciences News Headlines

$1.91
+0.01 (+0.53 %)
(As of 05/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.85
$2.00
50-Day Range
$1.90
$3.26
52-Week Range
$1.85
$21.20
Volume447,018 shs
Average Volume5.05 million shs
Market Capitalization$41.79 million
P/E RatioN/A
Dividend YieldN/A
Beta1.81

Headlines

Enveric Biosciences (NASDAQ ENVB) News Headlines Today

SourceHeadline
Enveric Biosciences Appoints Dr. Arash Asher to Scientific Advisory BoardEnveric Biosciences Appoints Dr. Arash Asher to Scientific Advisory Board
finance.yahoo.com - May 12 at 8:30 AM
Enveric Biosciences (NASDAQ:ENVB)  Shares Down 10% Enveric Biosciences (NASDAQ:ENVB) Shares Down 10%
americanbankingnews.com - May 11 at 12:57 AM
Enveric Biosciences to Participate in the Planet MicroCap Showcase on April 21stEnveric Biosciences to Participate in the Planet MicroCap Showcase on April 21st
finance.yahoo.com - April 14 at 9:22 AM
Enveric Biosciences Names Carter Ward CFO - Quick FactsEnveric Biosciences Names Carter Ward CFO - Quick Facts
markets.businessinsider.com - April 12 at 8:11 AM
Enveric Biosciences Appoints Carter Ward as Chief Financial OfficerEnveric Biosciences Appoints Carter Ward as Chief Financial Officer
finance.yahoo.com - April 12 at 8:11 AM
Enveric Biosciences CEO describes how the group has multiple shots on goal with current pipelineEnveric Biosciences CEO describes how the group has 'multiple shots on goal' with current pipeline
proactiveinvestors.com - April 7 at 2:22 PM
Enveric Biosciences Reports Full Year 2020 Financial Results and Provides Shareholder Update on its Accomplishments in 2021Enveric Biosciences Reports Full Year 2020 Financial Results and Provides Shareholder Update on its Accomplishments in 2021
finance.yahoo.com - April 1 at 9:29 AM
Enverics Patient-Centric Model to Enhance the Quality of Life of Cancer PatientsEnveric's Patient-Centric Model to Enhance the Quality of Life of Cancer Patients
msn.com - March 24 at 10:40 AM
Enveric Biosciences Appoints Dr. Douglas D. Lind to Companys Board of DirectorsEnveric Biosciences Appoints Dr. Douglas D. Lind to Company's Board of Directors
finance.yahoo.com - March 18 at 11:51 AM
Enveric Biosciences Discusses Acquisition of Exclusive License from Diverse Biotech and Value Catalysts Moving Forward in New Video Interview on SNN NetworkEnveric Biosciences Discusses Acquisition of Exclusive License from Diverse Biotech and Value Catalysts Moving Forward in New Video Interview on SNN Network
finance.yahoo.com - March 17 at 12:50 PM
Diverse Biotech announces Strategic Transaction with Enveric BiosciencesDiverse Biotech announces Strategic Transaction with Enveric Biosciences
finance.yahoo.com - March 16 at 10:14 AM
Enveric Biosciences to Participate in Upcoming Investor Conferences in MarchEnveric Biosciences to Participate in Upcoming Investor Conferences in March
finance.yahoo.com - March 15 at 8:50 AM
Enveric Biosciences Signs Definitive Agreement to Acquire Exclusive License for Novel Molecules from Diverse BiotechEnveric Biosciences Signs Definitive Agreement to Acquire Exclusive License for Novel Molecules from Diverse Biotech
finance.yahoo.com - March 10 at 8:27 AM
44 Stocks Moving in Thursdays Pre-Market Session44 Stocks Moving in Thursday's Pre-Market Session
msn.com - February 11 at 9:37 AM
Enveric Biosciences Inc. Announces $12.8 Million Registered Direct OfferingEnveric Biosciences Inc. Announces $12.8 Million Registered Direct Offering
finance.yahoo.com - February 9 at 1:13 PM
Enveric Biosciences, Inc. (ENVB)Enveric Biosciences, Inc. (ENVB)
au.finance.yahoo.com - January 26 at 11:04 PM
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Enveric Biosciences, Inc. for Potential Breaches of Fiduciary Duty By Its Board of DirectorsSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Enveric Biosciences, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
finance.yahoo.com - January 21 at 12:30 PM
Enveric Biosciences Issues Shareholder Letter Providing Strategic Vision for Advancing Novel Prescription Supportive Care Cancer TherapiesEnveric Biosciences Issues Shareholder Letter Providing Strategic Vision for Advancing Novel Prescription Supportive Care Cancer Therapies
finance.yahoo.com - January 19 at 3:24 PM
This page was last updated on 5/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.